<DOC>
	<DOCNO>NCT02373137</DOCNO>
	<brief_summary>The purpose study compare visual acuity outcomes two type endothelial keratoplasty : 1 ) Ultrathin Descemet 's Stripping Endothelial Keratoplasty ( DSAEK ) 2 ) Descemet 's Membrane Endothelial Keratoplasty ( DMEK ) . Half participant randomize DSAEK half DMEK .</brief_summary>
	<brief_title>Descemets Endothelial Thickness Comparison Trial</brief_title>
	<detailed_description>Corneal transplantation evolve rapidly recent year . Lamellar keratoplasty replace diseased endothelium lead fast recovery time , few complication , good visual acuity outcome . Currently , Descemet 's Stripping Endothelial Keratoplasty ( DSAEK ) common procedure relative ease good outcome . Newer techniques Descemet 's Membrane Endothelial Keratoplasty ( DMEK ) , Descemet 's membrane alone transplant , potential improve visual acuity outcome , produce few higher-order corneal aberration decrease rejection rate . However , donor preparation , increase intra-operative time , problem donor attachment DMEK important limitation . There three potential mechanism DMEK may provide good visual acuity outcomes DSAEK ; graft thickness , interface haze corneal higher-order aberration . Graft thickness correlate best spectacle correct visual acuity ( BSCVA ) outcomes among thin graft . One retrospective case series find 71 % thin endothelial graft ( define &lt; 131μm ) BSCVA 20/25 well 50 % thick graft ( define ≥131 ) achieve . In addition , higher-order aberration , particular posterior cornea , increase DSAEK . Theoretically , give decrease tissue transplant DMEK would lessen , however , one retrospective series look high order aberration DMEK compare DSAEK find difference posterior aberration central 4.0 mm zone two group . Finally , interface haze may increase DSAEK correlate BSCVA . Ultrathin DSAEK involve donor preparation deep microkeratome pas produce donor graft le 100 um thick . This procedure may similar result DMEK without technical difficulty . Several large prospective series show similar visual outcome result rate immunologic rejection ultrathin DSAEK DMEK , however comparison difficult . This comparative effectiveness clinical trial could directly address important issue . The investigator also anticipate secondary analysis trial data allow u address several .</detailed_description>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Tropicamide</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Damaged diseased endothelium Fuchs Pseudophakic Bullous Keratopathy Good candidate corneal transplantation either DMEK DSAEK Willingness ability undergo cornea transplantation Willingness participate followup visit Participants decisionally and/or cognitively impaired Participants suitable DMEK DSAEK surgeries Prior Endothelial Keratoplasty ( EK ) ophthalmic surgery except uncomplicated cataract surgery Indication surgery suitable EK ( e.g . keratoconus , stromal dystrophy scar ) Presence condition increase probability failure ( e.g. , heavily vascularize cornea , uncontrolled uveitis ) Other primary endothelial dysfunction condition include posterior polymorphous corneal dystrophy congenital hereditary corneal dystrophy Aphakia , anterior chamber intraocular lens ( IOL ) study eye prior anticipate EK Planned intraocular lens exchange anterior chamber IOL posterior chamber IOL study time study EK Preoperative central subepithelial stromal scar investigator believe visually significant could impact postoperative stromal clarity assessment Peripheral anterior synechiae ( iris angle ) angle great total three clock hour Hypotony ( Intraocular pressure &lt; 10mmHg ) Uncontrolled ( defined intraocular pressure &gt; 25mmHg ) glaucoma Visually significant optic nerve macular pathology Visually significant optic nerve macular pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>